EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BCOR ‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

Diego M Montoya-Cerrillo iD, Mark G Evans iD, Andrew Elliott, Renzo Calderon Anyosa, Jaylou Velez Torres, Elizabeth A Montgomery, Francis J Hornicek, H Thomas Temple, Brooke Crawford, Jonathan Trent iD, Emily E Jonczak iD, Gina D'Amato iD und 1 weitere

Genes, Chromosomes and Cancer · 2025

DOI: 10.1002/gcc.70068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2025. Verfasst von Diego M Montoya-Cerrillo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Chondrosarcoma, Proto-Oncogene Proteins, Repressor Proteins, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional and dedifferentiated chondrosarcoma encompass a group of malignant neoplasms that produce cartilaginous matrix and arise within or on the surface of bone. Conventional chondrosarcomas are graded on a three‐tiered scale, whereas dedifferentiated chondrosarcoma is typically not graded but is considered a high‐grade sarcoma and represents the most aggressive subtype with a poor prognosis. IDH1 (isocitrate dehydrogenase‐1) and I DH2 (isocitrate dehydrogenase‐2) are the most commonly mutated genes in conventional and dedifferentiated chondrosarcoma, followed in frequency by COL2A1 and TP53 . IDH1/2 driver mutations are also commonly found in enchondroma, considered a benign precursor lesion of chondrosarcoma, and other malignancies such as gliomas, cholangiocarcinoma, and acute myeloid leukemia. In acute myeloid leukemia, the presence of concurrent BCOR (BCL‐6 corepressor) loss‐of‐function mutations has been linked to disease relapse and resistance to treatment with IDH inhibitors. After identifying an index case of conventional chondrosarcoma with unusually aggressive clinical evolution, we investigated the clinicopathological features of 12 cases of BCOR ‐mutated conventional and dedifferentiated chondrosarcomas against a control group of 15 BCOR ‐wildtype (WT) cases to determine whether BCOR ‐mutated tumors had patterns of biological progression different from tumors with intact BCOR . All identified BCOR alterations led to loss‐of‐function by either missense or nonsense mutations. The prevalence of BCOR mutations occurred in 5% of conventional and dedifferentiated chondrosarcoma, and these were associated with larger tumor size ( p = 0.024), metastasis at the time of diagnosis ( p ≤ 0.001) and higher T category (3–4 vs. 1–2) ( p = 0.009). Although larger studies are necessary to clarify the full impact of BCOR mutations on patients with conventional and dedifferentiated chondrosarcoma, our data indicate that BCOR genetic aberrations are associated with adverse clinical features.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaProto-Oncogene ProteinsRepressor ProteinsMutationBone NeoplasmsMixed Function OxygenasesHumansFemaleMaleMiddle AgedAdultAged

Stichwörter der Autor:innen

BCORchondrosarcomaconventionaldedifferentiated

Substanzen

BCOR protein, humanProto-Oncogene ProteinsRepressor ProteinsMixed Function Oxygenases

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Caris Life Sciences, Irving, Texas, USA.
  • Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Division of Orthopedic Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA.

ORCID-Profile: Diego M Montoya-Cerrillo, Mark G Evans, Jonathan Trent, Emily E Jonczak, Gina D'Amato

Zitieren

APA

Montoya-Cerrillo, D. M., Evans, M. G., Elliott, A., Anyosa, R. C., Torres, J. V., Montgomery, E. A., Hornicek, F. J., Temple, H. T., Crawford, B., Trent, J., Jonczak, E. E., D'Amato, G., & Rosenberg, A. E. (2025). BCOR ‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70068

Vancouver

Montoya-Cerrillo DM, Evans MG, Elliott A, Anyosa RC, Torres JV, Montgomery EA, et al. BCOR ‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study. Genes, Chromosomes and Cancer. 2025. doi:10.1002/gcc.70068

BibTeX
@article{MontoyaCerrillo2025,
  author = {Montoya-Cerrillo, Diego M and Evans, Mark G and Elliott, Andrew and Anyosa, Renzo Calderon and Torres, Jaylou Velez and Montgomery, Elizabeth A and Hornicek, Francis J and Temple, H Thomas and Crawford, Brooke and Trent, Jonathan and Jonczak, Emily E and D'Amato, Gina and Rosenberg, Andrew E},
  title = {BCOR ‐Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study},
  journal = {Genes, Chromosomes and Cancer},
  year = {2025},
  doi = {10.1002/gcc.70068}
}
Kostenlos starten →